tiprankstipranks
Advertisement
Advertisement

DE:4AB Stock Latest News

AbbVie Apogee Deal Seen as Strategically Sensible but Not Thesis-Changing; Hold Rating and $244 Price Target Reiterated
RatingsAbbVie Apogee Deal Seen as Strategically Sensible but Not Thesis-Changing; Hold Rating and $244 Price Target Reiterated
5h ago
ABBV
Apogee Therapeutics downgraded to Hold from Buy at TD Cowen
PremiumThe Fly
Apogee Therapeutics downgraded to Hold from Buy at TD Cowen
3d ago
ABBV
APGE
AbbVie’s Allergan Aesthetics receives approval for Boey in Canada
PremiumThe Fly
AbbVie’s Allergan Aesthetics receives approval for Boey in Canada
3d ago
ABBV
Apogee Therapeutics price target raised to $135 from $97 at RBC Capital
PremiumThe Fly
Apogee Therapeutics price target raised to $135 from $97 at RBC Capital
3d ago
ABBV
APGE
Apogee Therapeutics moved to No Rating at BofA
PremiumThe Fly
Apogee Therapeutics moved to No Rating at BofA
3d ago
ABBV
APGE
AbbVie price target raised to $273 from $265 at Canaccord
PremiumThe FlyAbbVie price target raised to $273 from $265 at Canaccord
3d ago
ABBV
APGE
AbbVie announces European Commission approval for Skyrizi
Premium
The Fly
AbbVie announces European Commission approval for Skyrizi
3d ago
ABBV
AbbVie announces European Commission approval of Maviret
Premium
The Fly
AbbVie announces European Commission approval of Maviret
3d ago
ABBV
AbbVie announces EU approval of Skyrizi for pediatric patients
PremiumThe Fly
AbbVie announces EU approval of Skyrizi for pediatric patients
3d ago
ABBV
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street
PremiumThe Fly
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street
4d ago
ABBV
APGE
Midday Fly By: Chevron signs power deal with Microsoft, CRH to acquire Arcosa
PremiumThe Fly
Midday Fly By: Chevron signs power deal with Microsoft, CRH to acquire Arcosa
4d ago
MU
PR
Early notable gainers among liquid option names on June 22nd
PremiumThe Fly
Early notable gainers among liquid option names on June 22nd
4d ago
ON
ABBV
Video: SpaceX dips after notes offering, KeyBanc initiation
PremiumThe FlyVideo: SpaceX dips after notes offering, KeyBanc initiation
4d ago
ACA
CRH
AbbVie’s Strategic Pipeline and Immunology Expansion Support Buy Rating, Price Target Reaffirmed at $258
Premium
Ratings
AbbVie’s Strategic Pipeline and Immunology Expansion Support Buy Rating, Price Target Reaffirmed at $258
4d ago
ABBV
Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital
Premium
The Fly
Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital
4d ago
ABBV
APGE
AbbVie to Acquire Apogee, Expanding Immunology Portfolio
PremiumCompany Announcements
AbbVie to Acquire Apogee, Expanding Immunology Portfolio
4d ago
8K
ABBV
AbbVie to acquire Apogee Therapeutics for $10.9B in cash
PremiumThe Fly
AbbVie to acquire Apogee Therapeutics for $10.9B in cash
4d ago
ABBV
APGE
AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B
PremiumThe Fly
AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B
4d ago
ABBV
APGE
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
PremiumThe Fly
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
4d ago
ABBV
APGE
BTIG says others may be interested in Apogee Therapeutics
PremiumThe FlyBTIG says others may be interested in Apogee Therapeutics
4d ago
JNJ
NVS
AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo
Premium
The Fly
AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo
4d ago
ABBV
APGE
AbbVie near deal to acquire Apogee Therapeutics, FT reports
Premium
The Fly
AbbVie near deal to acquire Apogee Therapeutics, FT reports
4d ago
ABBV
APGE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >